Evidence map›Paper›PMID 32152679›Full record

ArticleCancer chemotherapy and pharmacology2020

Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.

Usman Arshad, Su-Arpa Ploylearmsaeng, Mats O Karlsson, Oxana Doroshyenko, Dorothee Langer, Edgar Schömig, Sabine Kunze, Semih A Güner, Roman Skripnichenko, Sami Ullah and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Usman Arshad *Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany. arshad_u@outlook.com.ORCID http://orcid.org/0000-0002-7003-5300
Su-Arpa Ploylearmsaeng *Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Mats O KarlssonDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Oxana DoroshyenkoFaculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Dorothee LangerFaculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Edgar SchömigFaculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Sabine KunzeDepartment of Radiotherapy, University Hospital Cologne, Cologne, Germany.
Semih A GünerDepartment of Radiotherapy, University Hospital Cologne, Cologne, Germany.
Roman SkripnichenkoDepartment of Radiotherapy, University Hospital Cologne, Cologne, Germany.
Sami UllahFaculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Ulrich JaehdeInstitute of Pharmacy, Clinical Pharmacy, University of Bonn, Bonn, Germany.
Uwe FuhrFaculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
Alexander Jetter *Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Max Taubert *Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany.
University of Cologne · DEUniversity Hospital Cologne · DEUniversity of Bonn · DEUppsala University · SEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe 5-fluorouracil (5FU) pharmacokinetics, myelotoxicity and respective covariates using a simultaneous nonlinear mixed effect modelling approach.

methodsThirty patients with gastrointestinal cancer received 5FU 650 or 1000 mg/m

resultsTotal clearance of 5FU correlated with body surface area (BSA). Population estimate for total clearance was 249 L/h. Clearances of 5FU and 5FUH2 fractionally changed by 77%/m

conclusionsBSA should be taken into account for predicting 5FU exposure. Myelosuppression was influenced by 5FU exposure and concomitant administration of cisplatin.

Indexed as

Models, BiologicalAdultAgedAntimetabolites, AntineoplasticFemaleFluorouracilFollow-Up StudiesGastrointestinal NeoplasmsHumansInfusions, IntravenousMaleMiddle AgedMyeloid CellsNonlinear DynamicsPrognosisTissue DistributionAntimetabolites, AntineoplasticFluorouracil5-FluorouracilMyelosuppressionPharmacodynamicsPharmacogeneticsPharmacokinetics

Identifiers

PMID32152679
PMCPMC7125253
OpenAlexW3009371075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.